SCHEMBL15919348

SCHEMBL15919348

O=C1CNC(=O)N1c1cc(-c2ccc(Br)cc2)nc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 2/20 0.43
CYP19A1 P11511 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TNKS O95271 1/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
TNKS2 Q9H2K2 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
GAA P10253 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
ALDH1A1 P00352 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15905041 0.80 MOK (0.43) KDM4EL3MBTL1LMNACYP19A1RAB9A
SCHEMBL15904904 0.74 CYP19A1 (0.41) CYP19A1GAAALDH1A1
SCHEMBL28247713 0.71 KDM4E (0.56) KDM4EL3MBTL1LMNACYP19A1RAB9A
SCHEMBL969768 0.69 ACACA (0.65) KDM4EL3MBTL1LMNAMAPTALDH1A1
SCHEMBL29400688 0.69 ACACA (0.65) KDM4EL3MBTL1LMNAMAPTALDH1A1
SCHEMBL28251703 0.69 ACACA (0.65) KDM4EL3MBTL1LMNAMAPTALDH1A1
SCHEMBL10864800 0.68 KMT2A (0.55) KDM4EL3MBTL1LMNANPC1RAB9A
SCHEMBL5795122 0.68 ESRRB (0.51) KDM4ELMNATNKSCYP1A1CYP1B1
SCHEMBL15919363 0.68 ACHE (0.77) KDM4ELMNACYP1A1CYP1B1RXFP1
SCHEMBL13715365 0.68 ACP1 (0.50) KDM4ELMNANPC1RAB9ATNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-9663488-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2017-05-30 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals (NC), Inc. 2015-12-10 US disclosed
WO-2014117090-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353546-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO KDM4E 3322/4885L3MBTL1 1568/4885LMNA 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.